Seres Therapeutics (MCRB) shares were down almost 14% in recent Thursday trading after Chardan downgraded the biotechnology company's stock to neutral from buy and cut its target price to $6 per share from $25.
Trading volume stood at over 164,000 shares compared with a daily volume of 73,257.
Price: 7.14, Change: -1.15, Percent Change: -13.87